Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development

Journal of Hepatology

Volumn 41, Issue 1, 2004, Pages 97-103

  Yoshiji, Hitoshi ^a   Kuriyama, Shigeki ^b   Yoshii, Junichi ^a   Ikenaka, Yasuhide ^a   Noguchi, Ryuichi ^a   Yanase, Koji ^a   Namisaki, Tadashi ^a   Kitade, Mitsuteru ^a   Yamazaki, Masaharu ^a   Tsujinoue, Hirohisa ^a   Masaki, Tsutomu ^b   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; flt 1 (VEGFR 1); Hepatocellular carcinoma; KDR Flk 1 (VEGFR 2); VEGF

Indexed keywords

MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ALLOGRAFT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 2542556259     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.03.001     Document Type: Article

References (41)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med. 9:2003;653-660
2. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21:2000;505-515
3. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257
4. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med. 9:2003;669-676
5. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 26:2001;25-35
6. Karkkainen M.J., Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 19:2000;5598-5605
7. Kanno S., Oda N., Abe M., Terai Y., Ito M., Shitara K., et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene. 19:2000;2138-2146
8. Kroll J., Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 272:1997;32521-32527
9. Petrova T.V., Makinen T., Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res. 253:1999;117-130
10. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 269:1994;26988-26995
11. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol. 33:2001;409-420
12. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 95:1998;9349-9354
13. Hiratsuka S., Maru Y., Okada A., Seiki M., Noda T., Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61:2001;1207-1213
14. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 8:2002;831-840
15. Befeler A.S., Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 122:2002;1609-1619
16. Schafer D.F., Sorrell M.F. Hepatocellular carcinoma. Lancet. 353:1999;1253-1257
17. Mise M., Arii S., Higashituji H., Furutani M., Niwano M., Harada T., et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 23:1996;455-464
18. Suzuki K., Hayashi N., Miyamoto Y., Yamamoto M., Ohkawa K., Ito Y., et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 56:1996;3004-3009
19. Yamaguchi R., Yano H., Nakashima Y., Ogasawara S., Higaki K., Akiba J., et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep. 7:2000;725-729
20. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 28:1998;68-77
21. Yoshiji H., Kuriyama S., Yoshii J., Yamazaki M., Kikukawa M., Tsujinoue H., et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology. 28:1998;1489-1496
22. Yoshiji H., Kuriyama S., Hicklin D.J., Huber J., Yoshii J., Miyamoto Y., et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology. 30:1999;1179-1186
23. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 89:1992;5547-5551
24. Yoshiji H., Harris S.R., Thorgeirsson U.P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 57:1997;3924-3928
25. Yoshiji H., Yoshii J., Ikenaka Y., Noguchi R., Yanase K., Tsujinoue H., et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol. 20:2002;1227-1231
26. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Hicklin D.J., et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology. 35:2002;834-842
27. Manzotti C., Audisio R.A., Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis. 11:1993;5-14
28. Kuriyama S., Yamazaki M., Mitoro A., Tsujimoto T., Kikukawa M., Tsujinoue H., et al. Hepatocellular carcinoma in an orthotopic mouse model metastasizes intrahepatically in cirrhotic but not in normal liver. Int J Cancer. 80:1999;471-476
29. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 7:2001;1194-1201
30. Hattori K., Heissig B., Wu Y., Dias S., Tejada R., Ferris B., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med. 8:2002;841-849
31. Yoshiji H., Kuriyama S., Hicklin D.J., Huber J., Yoshii J., Ikenaka Y., et al. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology. 33:2001;841-847
32. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:1999;5209-5218
33. Yoshiji H., Kuriyama S., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., et al. The angiotensin-i-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res. 7:2001;1073-1078
34. Yoshiji H., Harris S.R., Raso E., Gomez D.E., Lindsay C.K., Shibuya M., et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer. 75:1998;81-87
35. Yoshii J., Yoshiji H., Kuriyama S., Ikenaka Y., Noguchi R., Okuda H., et al. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer. 94:2001;768-773
36. Takahashi T., Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene. 14:1997;2079-2089
37. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 2:1996;689-692
38. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886
39. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 94:2002;883-893
40. Brekken R.A., Huang X., King S.W., Thorpe P.E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 58:1998;1952-1959
41. Benjamin L.E., Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA. 94:1997;8761-8766